Literature DB >> 27809610

Sexuality and quality of life in congenital hypogonadisms.

María Fernanda Garrido Oyarzún1, Camil Castelo-Branco2.   

Abstract

Turner syndrome and idiopathic congenital hypogonadism including Kallmann syndrome are conditions associated to a large number of widely known comorbidities that need a medical support forever. One of the characteristics shared by both conditions is the lack of sexual development that influencing the sexuality functioning and quality of life of the affected women. Few studies have been conducted to assess these topics, but they need to be considered in the treatment to all women with hypogonadism. This review on the major medical issues and psychological aspects, also focus in the present knowledge about sexual function and quality of life of women with Turner syndrome and idiopathic congenital hypogonadism, which aims to help in the comprehensive management of these patients.

Entities:  

Keywords:  Idiopathic hypogonadotropic hypogonadism; Kallmann syndrome; Turner syndrome; quality of life; sexual function

Mesh:

Year:  2016        PMID: 27809610     DOI: 10.1080/09513590.2016.1241229

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  3 in total

1.  Beyond hormone replacement: quality of life in women with congenital hypogonadotropic hypogonadism.

Authors:  Shota Dzemaili; Jitske Tiemensma; Richard Quinton; Nelly Pitteloud; Diane Morin; Andrew A Dwyer
Journal:  Endocr Connect       Date:  2017-07-11       Impact factor: 3.335

2.  Two Sisters with Kallmann Syndrome, Gonadal Dysgenesis, and Multiple Neuromuscular and Endocrine Disorders: Report of Two Cases with Description of an Unusual Association.

Authors:  Marta Camacho; Camil Castelo-Branco
Journal:  Reprod Sci       Date:  2022-02-23       Impact factor: 2.924

3.  A novel heterozygous mutation of CHD7 gene in a Chinese patient with Kallmann syndrome: a case report.

Authors:  Weiwei Xu; Weibin Zhou; Haiyang Lin; Dan Ye; Guoping Chen; Fengqin Dong; Jianguo Shen
Journal:  BMC Endocr Disord       Date:  2021-09-25       Impact factor: 2.763

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.